Table 2.
Patient Characteristics: MSK-IMPACT
| Characteristic | 9p24.1 (JAK2/PD-L1/PD-L2) amp (non-TNBC) | 9p24.1 (JAK2/PD-L1/PD-L2) amp (TNBC) | 9p24.1 (JAK2/PD-L1/PD-L2) del (non-TNBC) | 9p24.1 (JAK2/PD-L1/PD-L2) del (TNBC) |
|---|---|---|---|---|
| Total cases | 10 | 10 | 11 | 3 |
| Age in years, mean (range) | 55.1 (32–65) | 63.2 (38–75) | 53.7 (32–75) | 57.7 (53–62) |
| ER+, IHC | 6/9 (66.6%)∗ | 0/10 (0%) | 8/11 (72.7%) | 0/3 (0%) |
| PR+, IHC | 0/9 (0%)∗ | 0/10 (0%) | 4/11 (36.4%) | 0/3 (0%) |
| HER2+, IHC/FISH | 6/10 (60%) | 0/10 (0%) | 6/11 (54.5%) | 0/3 (0%) |
| ERBB2 FC, IMPACT, mean (IQ range) | +4.4 (−0.6 to +5.0) | −0.5 (−1.2 to +0.5) | +3.4 (+1.0–+7.4) | −1.2 (−1.3 to −1.1) |
| JAK2 FC, IMPACT, mean (IQ range) | +3.8 (+2.2–+3.3) | +3.3 (+2.5–+4.1) | −2.4 (−2.5 to −2.0) | −2.0 (−2.2 to −1.9) |
| PD-L1 FC, IMPACT, mean (IQ range) | +2.3 (+2.0–+2.8) | +3.3 (+2.5–+4.1) | −2.0 (−2.4 to −1.6) | −2.0 (−2.2 to −1.9) |
| PD-L2 FC, IMPACT, mean (IQ range) | +2.3 (+1.7–+3.2) | +3.2 (+2.5–+3.8) | −1.7 (−2.0 to −1.4) | −2.1 (−2.2 to −1.9) |
| Primary versus metastasis | P: 2/10 (20%) M: 8/10 (80%) |
P: 6/10 (60%) M: 4/10 (40%) |
P: 2/11 (18.2%) M: 9/11 (81.8%) |
P: 1/3 (33.3%) M: 2/3 (66.6%) |
| Primary with prior NAC | 1/2 (50%) | 2/6 (33.3%) | 2/2 (100%) | 1/1 (100%) |
| Metastasis with prior chemotherapy | 5/8 (62.5%) | 2/4 (50%) | 7/9 (77.7%) | 2/2 (100%) |
| Documented immunotherapy, yes/no | 1/10 (10%) | 1/10 (10%) | 0/11 (0%) | 0/3 (0%) |
Amp, amplification; Del, deletion; FC, fold change; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; IQ range, interquartile range; M, metastasis; MSK-IMPACT, Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets; NAC, neoadjuvant chemotherapy; P, primary; PR, progesterone receptor; TNBC, triple-negative breast cancer; ER, estrogen receptor.
∗
No ER/PR status was documented for one specimen.